United States Patent 8,802,137 (Claims Scope) and the US Liposomal Aminoglycoside Patent Landscape

US Patent 8,802,137 claims a specific class of liposomal aminoglycoside compositions and uses: liposomes with a neutral phospholipid plus sterol bilayer, encapsulated aminoglycoside, constrained lipid:drug weight ratios, and nanometer-scale mean particle diameter, followed by pulmonary infection treatment methods (including cystic fibrosis and specified pathogen classes) and a nebulized spray device format.

Because you provided only the claim text (and not the patent bibliographic record, assignee, priority dates, specification details, or the related family members), this analysis is limited strictly to what can be derived from the claim set itself: claim scope, claim-to-feature mapping, and the practical “design-around” and infringement risk contours that these claim elements create. A complete, citation-backed “patent landscape” by assignee, priority chain, expiration, Orange Book listing, FDA approval status, and Paragraph IV/Biosimilar risk requires bibliographic and regulatory inputs that are not present here.

What exactly does US Patent 8,802,137 claim: liposomal aminoglycoside formulation scope and feature-by-feature boundaries?

Independent claim 1 defines the protected product space. Every downstream claim (2–13 composition species; 14–33 treatment methods; 54–59 nebulized spray) depends on satisfying claim 1’s formulation limitations.

Core product limitations in claim 1

Claim 1 requires all of the following:

Liposomal aminoglycoside formulation
Liposome structure
- Lipid bilayer
- Neutral phospholipid + sterol in the bilayer
Active
- Aminoglycoside encapsulated inside the liposome
Compositional constraint
- Weight ratio of lipid to aminoglycoside ≤ 2:1
Particle size constraint
- Mean diameter 0.1 µm to 0.5 µm

Additional narrowing by dependent claims (2–13)

Aminoglycoside genus: amikacin, gentamicin, tobramycin.
Specific neutral phospholipid: DPPC (diphpalmitoylphosphatidylcholine).
Specific sterol: cholesterol.
Salt forms: sulfate salts (amikacin sulfate, gentamicin sulfate, tobramycin sulfate).

Net effect: claim 1 is broad on aminoglycoside selection (any aminoglycoside meeting “encapsulated therein,” with bilayer constraints and quantitative parameters). Claims 2–13 lock down the most commercially plausible aminoglycosides and lipid/sterol instantiations.

How broad are claim 1 boundaries: what does “lipid:aminoglycoside ≤ 2:1” and “mean diameter 0.1 to 0.5 µm” practically cover?

Claim 1 has two quantitative “gates” that are typically measurable and often become the center of infringement and validity disputes: (a) lipid:drug weight ratio and (b) mean vesicle diameter.

Lipid:aminoglycoside ratio

Protected region: formulations where the total lipid weight relative to aminoglycoside weight is ≤ 2:1.
Dependent tightening: claims 27–33 restrict this further to ≤ 0.75:1 (and other dependent ranges are “about 2:1 to about 0.5:1” and “about 1:1 to about 0.5:1”).

Implication for scope

Any accused product with >2:1 lipid:aminoglycoside falls outside the strict terms of claim 1, unless a doctrine-of-equivalents theory is pursued (outside this claim-text analysis).
Any accused product engineered to land near the boundary will create a factual fight around how the ratio is calculated:
- What counts as “lipid” (only phospholipid or includes sterol and other excipients)?
- How “aminoglycoside” is defined (free vs total encapsulated vs sulfate salt basis)?
- How measurement conditions are standardized (formulation stage vs post-processing).

Vesicle size gate: 0.1–0.5 µm mean diameter

Protected region: mean particle diameter between 0.1 µm and 0.5 µm.

Implication for scope

Many liposome platforms target sub-100 nm sizes; those generally sit below 0.1 µm and may fall outside claim 1 if mean diameter is below the lower bound.
Conversely, multilamellar or larger vesicles can exceed 0.5 µm and fall outside the claim’s size window.
If an accused formulation measures “mean” differently (intensity-weighted vs number-weighted, DLS vs NTA reporting conventions), the infringement analysis becomes measurement-method dependent.

Which aminoglycosides and lipid systems are explicitly covered: amikacin, gentamicin, tobramycin; DPPC and cholesterol?

The claim set explicitly covers the following combinations via dependent claims:

Aminoglycoside scope

Amikacin (claim 3)
Gentamicin (claim 4)
Tobramycin (claim 5)

Plus generic “aminoglycoside” in claim 1 (claim 2).

Salt and counterion scope

Aminoglycoside sulfate (claim 10)
Amikacin sulfate (claim 11)
Gentamicin sulfate (claim 13)
Tobramycin sulfate (claim 12)

Lipid and sterol scope

Neutral phospholipid = DPPC (claim 6 and the DPPC/cholesterol combination claims)
Sterol = cholesterol (claim 7)
DPPC + cholesterol together (claims 8 and 9)

Net effect: The “center of gravity” of the claim set is a DPPC/cholesterol bilayer, with cholesterol as the sterol component, carrying an aminoglycoside payload at a relatively low lipid:drug loading (≤2:1, and in some claims ≤0.75:1), sized in the 100–500 nm band.

What pulmonary infections are covered by the method claims, and how does cystic fibrosis fit into claim scope?

Independent method protection is claim 14:

Treating a patient for pulmonary infection by administering a therapeutically effective amount of the formulation of claim 1.

Pathogen lists in claims 15 and 17

Claim 15 (general pulmonary infection) and claim 17 (same list, but in the cystic fibrosis method) specify pathogens including:

Pseudomonas
staphylococcal
streptococcal
Escherichia
Klebsiella (spelled “Kiebsiella” in the claim text)
Enterobacter
Serratia
Haemophilus
Yersinia
Burkholderia
mycobacterial infection

Claim 18 and 19 narrow specifically to mycobacterial infection, and claim 20/21 enumerate species, including:

Mycobacterium tuberculosis
MAC (Mycobacterium avium and Mycobacterium intracellulare)
Mycobacterium kansasii
Mycobacterium xenopi
Mycobacterium marinum
Mycobacterium ulcerans
Mycobacterium fortuitum complex (M. fortuitum and M. chelonae)

Specific narrowing to Pseudomonas in claims 22–26

Claim 22: Pseudomonas infection
Claim 23: chronic Pseudomonas infection
Claim 24: Pseudomonas infection (within claim 17 dependent framework)
Claim 25/26: Pseudomonas aeruginosa infection

Cystic fibrosis method (claim 16)

Claim 16 requires administering the claim 1 formulation to a cystic fibrosis patient for a pulmonary infection, with claim 17 narrowing to the same pathogen list and claim 19 narrowing to mycobacterial infection.

Net effect: The method claims are structured to give coverage to:

broad pulmonary infection treatment using the claimed formulation,
CF-specific administration,
pathogen-class-specific embodiments (especially mycobacteria and Pseudomonas aeruginosa).

How strong is the claim strategy for litigation: product claims plus method claims plus delivery device format?

The claim set has three enforcement “angles”:

Product claims (claim 1 + composition dependents 2–13)
Infringement risk anchors on whether an accused liposomal formulation satisfies:
- bilayer composition (neutral phospholipid + sterol),
- payload encapsulation,
- lipid:drug ratio ≤2:1,
- mean diameter 0.1–0.5 µm.
Method-of-use claims (claims 14–33)
If product claims are hard to prove due to measurement, method claims can be enforced via:
- clinical use instructions, labeling, or prescribing patterns,
- specific patient group (CF),
- pathogen targets (mycobacteria, Pseudomonas).
Nebulized spray claims (claims 54–59)
These are format-dependent product-by-device claims. They tie the formulation to a nebulized spray delivery format, but only for the embodiments corresponding to claims 1/3/6/7/8/9 (based on your claim excerpt).

Practical effect: A defendant must navigate both formulation parameters and downstream “how it is administered” narratives. A plaintiff can choose the easiest infringement theory depending on available data: particle sizing/ratio testing vs. clinical labeling and device delivery evidence.

What formulations are definitively covered via the nested dependent ratios (0.75:1; about ranges), and how does that affect design-around?

Claims 27–33 set a tighter ratio threshold of ≤0.75:1, layered onto different method claim paths (general pulmonary infection, CF method, mycobacterial, Pseudomonas). Claims 36–44 set “about 2:1 to about 0.5:1” ranges for corresponding method embodiments. Claims 45–53 set “about 1:1 to about 0.5:1” ranges.

Coverage map by ratio term (from your excerpt)

Claim 1: lipid:aminoglycoside ≤2:1
Claims 27–33: lipid:aminoglycoside ≤0.75:1
Claims 36–44: lipid:aminoglycoside ~2:1 to ~0.5:1
Claims 45–53: lipid:aminoglycoside ~1:1 to ~0.5:1

Design-around consequence

Moving the formulation above 2:1 is an express exit from claim 1’s composition requirement.
Moving the formulation below 0.5:1 is not an express exclusion because “about” ranges appear in dependent method claims; but claim 1 only requires ≤2:1, so staying within size range and bilayer rules still keeps claim 1 risk.
The strongest “safe harbor” move relative to the claim text is (a) lipid:aminoglycoside > 2:1 and/or (b) mean diameter outside 0.1–0.5 µm, and/or (c) removing at least one bilayer component requirement (neutral phospholipid or sterol).

What does “neutral phospholipid + sterol” exclude: do charged phospholipids, different sterols, or mixed lipid bilayers fall outside?

Claim 1 requires the bilayer to comprise:

a neutral phospholipid and
a sterol.

Exclusion by omission

A bilayer that omits a sterol would likely fail.
A bilayer that uses only charged phospholipids and no neutral phospholipid would likely fail.
A bilayer that uses neutral phospholipid but no sterol would likely fail.

Sterol specificity

Claim 7 fixes cholesterol as one embodiment. Claim 1 does not limit sterol to cholesterol, only to “a sterol.” So other sterols can still fall under claim 1 as long as they satisfy the “sterol” definition in the claim and the bilayer composition requirement.

Neutral phospholipid specificity

Claim 6 fixes DPPC as one embodiment. Claim 1 is broader, so other neutral phospholipids can still fall under claim 1, depending on whether they qualify as “neutral phospholipid” under the claim construction.

Net effect: claim 1 is broad on what sterol and neutral phospholipid can be, but strict on the presence of both classes and on quantifiable ratio/size.

How does US Patent 8,802,137 compare with typical liposomal antibiotic patent families: where is the “novelty hook” in claim structure?

Even without the specification, the claim structure suggests the novelty hook is a constrained formulation envelope:

Encapsulation of aminoglycoside
Neutral phospholipid + sterol bilayer
Low lipid:aminoglycoside loading (≤2:1)
Vesicle mean diameter 0.1–0.5 µm
Pulmonary infection treatment use, including CF and specified pathogen classes
Nebulized spray delivery format

This is materially more specific than generic liposome-with-drug claims and more narrow than “any liposomal aminoglycoside.” The quantitative and structural gating features are typical of patents designed to:

carve out earlier liposome art with different particle size regimes,
distinguish from higher lipid:drug loading approaches,
target inhaled lung delivery where particle size and formulation loading affect deposition and tolerability.

What generic entry risks exist if a competitor makes a “nearby” liposomal aminoglycoside for inhalation?

Using only claim boundaries, the generic entry risk is highest when the competitor:

uses a liposomal delivery system,
ensures the aminoglycoside is encapsulated in the bilayer-associated vesicle,
includes neutral phospholipid + sterol in the bilayer,
uses lipid:drug ≤2:1, and
produces vesicles with mean diameter 0.1–0.5 µm.

Likely infringement “failure modes” for competitors (design-outs)

A competitor can reduce claim 1 exposure by moving at least one key element outside the claim:

Increase lipid:aminoglycoside above 2:1
Reduce mean vesicle diameter below 0.1 µm (or increase above 0.5 µm)
Remove the sterol component
Use a bilayer without a neutral phospholipid component
Avoid nebulized spray delivery if the only asserted theory uses claims 54–59 (though product and method claims would remain possible)

Litigation “pressure points”

Dosing-stage measurement of ratio
Particle sizing platform and reporting method for mean diameter
Evidence that the aminoglycoside is truly encapsulated (vs. surface-associated or complexed outside vesicles)
Labeling and clinical trial protocol evidence for method claims (CF, mycobacteria, Pseudomonas aeruginosa, chronic Pseudomonas)

What patent estate questions matter most for US 8,802,137: continuations, formulation dependents, and claim survivability?

With only the claim text, the estate-level questions cannot be completed, including:

whether there are continuations with different ratio/size boundaries,
whether there are parallel claims for alternate inhalation devices or routes,
whether there are composition claims covering manufacturing methods,
whether the patent is part of a family with broader genus coverage in other jurisdictions,
which assignees own blocking or complementary rights.

This section is therefore restricted to the claim-text-driven logic: the dependent claim ladder creates multiple assertion points that can survive partial invalidity if:

claim 1 remains valid and covers a wide range under ≤2:1 and 0.1–0.5 µm, then many dependent composition and method claims remain effective, and
even if narrowed dependent ratio thresholds are invalid, the independent claim can still anchor infringement.

Key claim-to-coverage matrix for US 8,802,137 (from your provided claims)

Claim	What it protects	Key constraints
1	Liposomal aminoglycoside formulation	Bilayer: neutral phospholipid + sterol; aminoglycoside encapsulated; lipid:aminoglycoside ≤2:1; mean diameter 0.1–0.5 µm
2	Genus species	Aminoglycoside = amikacin/gentamicin/tobramycin
3–5	Specific aminoglycoside	amikacin; gentamicin; tobramycin
6	Neutral phospholipid	DPPC
7	Sterol	cholesterol
8–9	DPPC + cholesterol	plus specific aminoglycoside combinations
10–13	Salt forms	aminoglycoside sulfate and specific sulfates
14	Pulmonary infection method	administer therapeutically effective amount of claim 1 formulation
15	Pathogen list (general)	includes Pseudomonas, staph/strep, Enterobacterales genera, Haemophilus, Burkholderia, mycobacteria
16	CF method	administer to cystic fibrosis patient
17	Pathogen list (CF)	same pathogen list as claim 15
18–21	Mycobacterial methods	mycobacterial infection and enumerated species (TB, MAC, kansasii, xenopi, marinum, ulcerans, fortuitum complex)
22–26	Pseudomonas methods	Pseudomonas; chronic Pseudomonas; P. aeruginosa
27–33	Ratio narrowed for methods	≤0.75:1 applied across method branches
36–44	“About” lipid:drug ranges for methods	~2:1 to ~0.5:1
45–53	“About” lipid:drug ranges for methods	~1:1 to ~0.5:1
54–59	Nebulized spray	nebulized spray comprising formulation tied to claim 1 and select dependents

Key Takeaways

US 8,802,137 claim 1 is the enforceable core: encapsulated aminoglycoside in a liposome bilayer with neutral phospholipid + sterol, with lipid:aminoglycoside ≤2:1 and mean diameter 0.1–0.5 µm.
Dependent claims lock in key commercialization parameters: amikacin/gentamicin/tobramycin, DPPC/cholesterol, and sulfate salts.
Method claims cover pulmonary infections, with targeted breadth for cystic fibrosis, mycobacterial species, and Pseudomonas aeruginosa including chronic Pseudomonas.
Nebulized spray claims create an additional enforcement angle tied to the formulation embodiment(s).
The most direct design-arounds, based on claim text, are to push outside at least one of the formulation gates: ratio (>2:1), size (<0.1 µm or >0.5 µm), or bilayer composition (no sterol or no neutral phospholipid).

FAQs

Can a liposomal aminoglycoside with vesicle size below 0.1 µm avoid claim 1?
Does using cholesterol as the sterol automatically satisfy the “sterol” element of claim 1?
If an accused product has lipid:aminoglycoside just above 2:1, does that eliminate infringement under the literal claim text?
Do the mycobacterial species enumerations in claims 20–21 create narrower infringement pathways than the broader “mycobacterial infection” in claims 18–19?
How do nebulized spray claims (54–59) interact with formulation and method claims when the route of administration differs?

References

No sources were provided or cited in the prompt beyond the claim text itself, and no bibliographic or regulatory records for US Patent 8,802,137 were included.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003304204	⤷ Start Trial
Australia	2006270008	⤷ Start Trial
Brazil	0315868	⤷ Start Trial
Brazil	PI0613865	⤷ Start Trial
Canada	2504317	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,802,137

Summary for Patent: 8,802,137